Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy

3' education - Nov. 15, 2023 - Ahmad Masri, MD - Portland, OR, US

Educational information

This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, US.

Faculty

Ahmad Masri is a cardiologist at OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis in Portland, OR, US.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Read our summary of the primary analysis of the ATTRibute-CM-trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.